Background

Over the past three or four years, we have seen the biggest collection of patent expiries in history.
— Stephen Whitehead, CEO of the Association of the British Pharmaceutical Industry, Nov 2014
 
 
A4-graphs 04 - _shifting paradigm.png

Pharmaceutical strategies are increasingly unstable in the post-blockbuster era.  Product pipelines are dwindling and the bar for acceptance of new active molecules is rising. The cost of pharmaceutical R&D per NCE launch has doubled roughly every 9 years since the 50s.  

We know, however, that there are untapped opportunities to bring new products to market at low cost. Pharmaceutical production has never been cheaper. There are abundant opportunities to develop new and improved pharmaceutical products for under-served populations of patients.

Small Pharma is built to capture these opportunities. With specific expertise in intellectual property (IP) analysis, we focus on developing intelligently improved pharmaceutical products.